Skip to main content
Equibles
HOWL logo

HOWL · Werewolf Therapeutics, Inc. · Metrics

Track HOWL — free

Use HOWL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research HOWL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.90 -0.03 (-2.79%) At close · Oct 5
Rebalance outlook locked
Going-concern doubt — flagged Jul 31, 2026

Substantial doubt about the company's ability to continue as a going concern.

“We believe there is substantial doubt about our ability to continue as a going concern for at least twelve months from the date that these condensed consolidated financial statements are issued in this Quarterly Report. We are currently evaluating strategies to raise additional capital, however, there can be no assurances that we will be successful in mitigating the conditions which raise substantial doubt about our ability to continue as a going concern in the near term, if at all.”
View the 10-Q filed Jul 31, 2026
Market Cap
$46.65M
Shares
48.60M
Volume · Oct 5 239.09K Avg daily vol (3M) 6.84M

HOWL metrics

51 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.93
Market cap
$46.65M

Price action

20 metrics
Price change (1W)
-3.3%
Price change (30D)
-5.3%
Price change (3M)
+173.0%
Price change (6M)
-8.1%
Price change (YTD)
+46.4%
Price change (1Y)
-51.7%
Trailing year
Price change (5Y)
-94.6%
52-week high
$2.05
52-week low
$0.31
Change from 52-week high
-54.7%
Change from 52-week low
+201.3%
Annualized volatility
143.9%
Annualized volatility (3M)
225.1%
Beta
2.1
RSI (14D)
55.7
Price vs SMA 50
+26.3%
Price vs SMA 200
+42.8%
Avg volume (3M)
6.84M
Relative volume
0.1
Average dollar volume
$5.41M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
48.60M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
2.9
reciprocal yield 34.9%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-74.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$31.26M
Net income (TTM)
−$34.61M
Trailing 12 months
Diluted EPS (TTM)
$-0.73
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.51

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+8.0%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-212.5%
Return on assets
-143.3%
Debt / equity
—
Current ratio
2.9
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
2.9
Interest coverage
-6.9
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$21.99M
Total assets
$24.16M
Total debt
$32.09M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$30.15M
Capital expenditures (TTM)
$0
R&D (TTM)
$32.91M
SG&A (TTM)
—
Stock compensation (TTM)
$3.79M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
46
13F filer change QoQ
-2
Institutional ownership
22.5%

Short interest

3 metrics
Short interest
3.5%
Latest settlement · 1.9 days to cover
Days to cover
1.9d
Short-squeeze score
57 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1785530 CUSIP 95075A107 13F (30d) 1 filings 1 filers Visit website Investor relations